CY2013015I1 - Πολυμορφο του 4-[2-[4-[1-(2-αιθοξυαιθυλ)-1η-βενζιμιδαζολ-2-υλ]-1-πιπepιδινυλ]αιθυλ]αιθυλ-αλφα, αλφα-διμεθυλ-βενζενοξικου οξεος - Google Patents

Πολυμορφο του 4-[2-[4-[1-(2-αιθοξυαιθυλ)-1η-βενζιμιδαζολ-2-υλ]-1-πιπepιδινυλ]αιθυλ]αιθυλ-αλφα, αλφα-διμεθυλ-βενζενοξικου οξεος

Info

Publication number
CY2013015I1
CY2013015I1 CY2013015C CY2013015C CY2013015I1 CY 2013015 I1 CY2013015 I1 CY 2013015I1 CY 2013015 C CY2013015 C CY 2013015C CY 2013015 C CY2013015 C CY 2013015C CY 2013015 I1 CY2013015 I1 CY 2013015I1
Authority
CY
Cyprus
Prior art keywords
alpha
ethyl
pipepidinyl
polyform
benzimidazol
Prior art date
Application number
CY2013015C
Other languages
English (en)
Other versions
CY2013015I2 (el
Original Assignee
Faes Farma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2013015(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma, S.A. filed Critical Faes Farma, S.A.
Publication of CY2013015I1 publication Critical patent/CY2013015I1/el
Publication of CY2013015I2 publication Critical patent/CY2013015I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY2013015C 2002-04-19 2013-04-24 Πολυμορφο του 4-[2-[4-[1-(2-αιθοξυαιθυλ)-1η-βενζιμιδαζολ-2-υλ]-1-πιπepιδινυλ]αιθυλ]αιθυλ-αλφα, αλφα-διμεθυλ-βενζενοξικου οξεος CY2013015I2 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000194 WO2003089425A1 (es) 2002-04-19 2002-04-19 POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO

Publications (2)

Publication Number Publication Date
CY2013015I1 true CY2013015I1 (el) 2015-08-05
CY2013015I2 CY2013015I2 (el) 2015-08-05

Family

ID=29225789

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071100259T CY1107564T1 (el) 2002-04-19 2007-02-23 Πολυμορφο του 4-[2-[4-[1-(2-αιθοξυαιθυλ)-1η-βενζιμιδαζολ-2-υλ]-1-πιπepιδινυλ]αιθυλ]αιθυλ-αλφα, αλφα-διμεθυλ-βενζενοξικου οξεος
CY2013015C CY2013015I2 (el) 2002-04-19 2013-04-24 Πολυμορφο του 4-[2-[4-[1-(2-αιθοξυαιθυλ)-1η-βενζιμιδαζολ-2-υλ]-1-πιπepιδινυλ]αιθυλ]αιθυλ-αλφα, αλφα-διμεθυλ-βενζενοξικου οξεος

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071100259T CY1107564T1 (el) 2002-04-19 2007-02-23 Πολυμορφο του 4-[2-[4-[1-(2-αιθοξυαιθυλ)-1η-βενζιμιδαζολ-2-υλ]-1-πιπepιδινυλ]αιθυλ]αιθυλ-αλφα, αλφα-διμεθυλ-βενζενοξικου οξεος

Country Status (31)

Country Link
US (2) US7612095B2 (el)
EP (1) EP1505066B1 (el)
JP (1) JP5142448B2 (el)
KR (1) KR100673140B1 (el)
CN (1) CN1290843C (el)
AR (1) AR039423A1 (el)
AT (1) ATE347550T1 (el)
AU (1) AU2002255017B2 (el)
BG (1) BG66302B1 (el)
BR (1) BRPI0215703B8 (el)
CA (1) CA2484460C (el)
CY (2) CY1107564T1 (el)
CZ (1) CZ305162B6 (el)
DE (1) DE60216641T2 (el)
DK (1) DK1505066T3 (el)
ES (1) ES2278018T3 (el)
HK (1) HK1072772A1 (el)
HR (1) HRP20041048B1 (el)
HU (1) HU230032B1 (el)
IL (1) IL164645A (el)
MX (1) MXPA04010313A (el)
NO (1) NO329327B1 (el)
NZ (1) NZ536551A (el)
PA (1) PA8571201A1 (el)
PE (1) PE20040086A1 (el)
PT (1) PT1505066E (el)
SI (1) SI1505066T1 (el)
SK (1) SK288052B6 (el)
UA (1) UA76866C2 (el)
UY (1) UY27762A1 (el)
WO (1) WO2003089425A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
JP6023054B2 (ja) * 2011-06-30 2016-11-09 パナソニック インテレクチュアル プロパティ コーポレーション オブ アメリカＰａｎａｓｏｎｉｃ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｃｏｒｐｏｒａｔｉｏｎ ｏｆ Ａｍｅｒｉｃａ 通信システム、ユーザ端末並びに通信装置
CN102675101B (zh) * 2012-05-16 2014-01-29 王蕾 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法
CZ307500B6 (cs) 2012-08-15 2018-10-24 Zentiva, K.S. Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103356616A (zh) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 一种含有比拉斯汀的药物组合物及其制备方法
CN104447682A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 比拉斯汀化合物
CN104398481A (zh) * 2014-10-29 2015-03-11 万全万特制药江苏有限公司 比拉斯汀口崩片及其制备方法
EP3327012B1 (en) 2015-07-24 2021-03-17 Urquima, S.A. Crystalline forms of bilastine and preparation methods thereof
EP3170817A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Co-crystals of benzimidazole compounds
EP3170816A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Supersaturated compositions of benzimidazole compounds
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
EP3452462A4 (en) * 2016-05-05 2019-10-23 MSN Laboratories Private Limited, R&D Center SOLID STATE FORMS OF 2- [4- (2- {4- [1- (2-ETHOXYETHYL) -1H-BENZIMIDAZOL-2-YL] -1-PIPERIDINYL} ETHYL) PHENYL] -2-METHYLPROPANOIC ACID AND PREPARATION METHOD THEREOF
ES2813561T3 (es) 2017-09-07 2021-03-24 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica en comprimido que comprende bilastina
ES2835287T3 (es) 2017-12-18 2021-06-22 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio
ES2773756R1 (es) * 2017-12-18 2021-04-12 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua
MX2020007692A (es) 2018-01-18 2020-09-14 Faes Farma Sa Composiciones oftalmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificacion.
CA3200779A1 (en) 2020-12-23 2022-06-30 Strusi ORAZIO LUCA A non-micronized bilastine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
CZ20013711A3 (cs) * 1999-04-16 2002-07-17 Dr. Reddy's Research Foundation Nové polymorfní formy antidiabetických činidel, způsob jejich přípravy a farmaceutické prostředky s jejich obsahem
AU765005B2 (en) * 1999-04-23 2003-09-04 Smithkline Beecham Plc Polymorph of 5-(4-(2- (N-methyl-N-( 2-pyridyl)amino) ethoxy)benzyl) thiazolidine-2,4-dione, maleic acid salt

Also Published As

Publication number Publication date
BR0215703A (pt) 2005-02-01
IL164645A0 (en) 2005-12-18
EP1505066A1 (en) 2005-02-09
CA2484460A1 (en) 2003-10-30
MXPA04010313A (es) 2005-06-08
EP1505066B1 (en) 2006-12-06
PT1505066E (pt) 2007-03-30
DE60216641T2 (de) 2007-09-27
HK1072772A1 (en) 2005-09-09
CA2484460C (en) 2009-09-29
CN1628112A (zh) 2005-06-15
JP5142448B2 (ja) 2013-02-13
US20050203141A1 (en) 2005-09-15
SI1505066T1 (sl) 2007-04-30
WO2003089425A1 (es) 2003-10-30
CZ20041122A3 (cs) 2005-03-16
PE20040086A1 (es) 2004-04-27
UA76866C2 (uk) 2006-09-15
SK50202004A3 (sk) 2005-05-05
NO20044999L (no) 2005-01-14
BRPI0215703B1 (pt) 2017-06-27
ATE347550T1 (de) 2006-12-15
CY1107564T1 (el) 2013-03-13
IL164645A (en) 2010-11-30
BG108941A (en) 2005-12-30
PA8571201A1 (es) 2003-12-10
CZ305162B6 (cs) 2015-05-27
NO329327B1 (no) 2010-09-27
HRP20041048A2 (en) 2005-02-28
DE60216641D1 (de) 2007-01-18
HU230032B1 (hu) 2015-05-28
AU2002255017A1 (en) 2003-11-03
BRPI0215703B8 (pt) 2021-05-25
ES2278018T3 (es) 2007-08-01
KR100673140B1 (ko) 2007-01-22
CN1290843C (zh) 2006-12-20
DK1505066T3 (da) 2007-03-19
US7612095B2 (en) 2009-11-03
NZ536551A (en) 2006-08-31
JP2005529120A (ja) 2005-09-29
KR20050005448A (ko) 2005-01-13
HRP20041048A9 (hr) 2013-01-31
CY2013015I2 (el) 2015-08-05
SK288052B6 (sk) 2013-03-01
HUP0500241A2 (hu) 2005-06-28
HRP20041048B1 (hr) 2013-04-30
US20100004285A1 (en) 2010-01-07
AU2002255017B2 (en) 2008-11-13
BG66302B1 (bg) 2013-03-29
AR039423A1 (es) 2005-02-16
UY27762A1 (es) 2003-09-30

Similar Documents

Publication Publication Date Title
CY2013015I2 (el) Πολυμορφο του 4-[2-[4-[1-(2-αιθοξυαιθυλ)-1η-βενζιμιδαζολ-2-υλ]-1-πιπepιδινυλ]αιθυλ]αιθυλ-αλφα, αλφα-διμεθυλ-βενζενοξικου οξεος
NO2017035I1 (no) Nintedanib, 3-Z-{1-(4-(N-((4-metyl-piperazin-1-y-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenylmetylenj- 6-metoksykarbonyl-2-indolinon
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
NO20050652L (no) Pyrrolidone derivater som maob inhibitorer
IS7667A (is) Nýjar bensimídazólafleiður
DE60330227D1 (de) N3-alkylierte benzimidazol-derivate als mek-hemmer
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
DE602004012154D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
NO20052487D0 (no) 1-(4-benzyl-piperazin-1-yl)-3-fenyl-propenonderivater.
ATE386518T1 (de) Benzimidazolderivate
DE50306063D1 (de) Abgasnachbehandlungsanordnung
DK1311488T3 (da) Substituerede imidazoler som tafia-inhibitorer
NO20053753D0 (no) Karboksylsyreforbindelser.
NO20043457L (no) 3-(imidazolyl)-2-alkoksypropansyrer som TAFIA inhibitorer
DE60324703D1 (de) Barbitursäure derivaten.
ITMI20020198A0 (it) (per)aloeteri
ITTO20020782A1 (it) Convertitore dc-dc.
ITTO20030578A1 (it) Convertitore push-pull, in particolare per
DE50308742D1 (de) Medikament-dosimeter-kombipackung
FI20020849A0 (fi) Menetelmä tekstiilin käsittelyyn
ITMI20020966A0 (it) Composti attivi contro i rhinovirus
DE50306664D1 (de) Zimtsäureamide
DE60335380D1 (de) Muskarine agonisten
UA7327S (uk) Ємкість для фармацевтичних засобів
ITMO20030236A1 (it) Macchina operatrice per la movimentazione di carichi.